The Efficacy and Safety of Shen Guo Lao Nian Granule for Common Cold of Qi-Deficiency Syndrome: Study Protocol for a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase II Clinical Trial

Abstract EN

Background.

Common cold is one of the most frequently occurring illnesses in primary healthcare services and represents considerable disease burden.

Common cold of Qi-deficiency syndrome (CCQDS) is an important but less addressed traditional Chinese medicine (TCM) pattern.

We designed a protocol to explore the efficacy, safety, and optimal dose of Shen Guo Lao Nian Granule (SGLNG) for treating CCQDS.

Methods/Design.

This is a multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial.

A total of 240 eligible patients will be recruited from five centers.

Patients are randomly assigned to high-dose group, middle-dose group, low-dose group, or control group in a 1 : 1 : 1 : 1 ratio.

All drugs are required to be taken 3 times daily for 5 days with a 5-day follow-up period.

Primary outcomes are duration of all symptoms, total score reduction on Jackson’s scale, and TCM symptoms scale.

Secondary outcomes include every single TCM symptom duration and score reduction, TCM main symptoms disappearance rate, curative effects, and comparison between Jackson’s scale and TCM symptom scale.

Ethics and Trial Registration.

This study protocol was approved by the Ethics Committee of Clinical Trials and Biomedicine of West China Hospital of Sichuan University (number IRB-2014-12) and registered with the Chinese Clinical Trial Registry (ChiCTR-IPR-15006349).